Condition
wAMD
Total Trials
4
Recruiting
0
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (3)
Trial Status
Active Not Recruiting4
Clinical Trials (4)
Showing 4 of 4 trials
NCT06668064Phase 3Active Not Recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06683742Phase 3Active Not Recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT05407636Phase 3Active Not Recruiting
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT04704921Phase 2Active Not Recruiting
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Showing all 4 trials